Black Diamond Therapeutics, Inc. (BDTX) Discusses Silevertinib Phase II Data and Phase III Development Plans Transcript

🇺🇸 Seeking Alpha (US) — 2026-11-10

Black Diamond Therapeutics discussed Phase II data for silevertinib and plans for Phase III development. The available description does not include the trial results or details of the development strategy.

Markets Health biotechnology silevertinib Phase II Phase III clinical development drug trials

Read original source →

Kano proposes N332bn for education in 2027
Punch Nigeria — 2026-11-11
Brazil electoral court fines Meta, sees no deliberate election bias
Deutsche Welle — 2026-11-11
Senate probes telecom firms over failed calls, airtime deductions
Punch Nigeria — 2026-11-11
Saudi Crude Output Jumps 26% as Riyadh Reports Near Pre-War Production
Oilprice.com — 2026-11-11
Triton International: Preferred Shares Are A High-Yielding Opportunity
Seeking Alpha — 2026-11-11
Canadian National Railway: A Fresh View From New Highs (Rating Downgrade)
Seeking Alpha — 2026-11-11

Black Diamond Therapeutics, Inc. (BDTX) Discusses Silevertinib Phase II Data and Phase III Development Plans Transcript

AI Summary

Related Articles

Kano proposes N332bn for education in 2027

Brazil electoral court fines Meta, sees no deliberate election bias

Senate probes telecom firms over failed calls, airtime deductions

Saudi Crude Output Jumps 26% as Riyadh Reports Near Pre-War Production

Triton International: Preferred Shares Are A High-Yielding Opportunity

Canadian National Railway: A Fresh View From New Highs (Rating Downgrade)